Tofersen for SOD1 amyotrophic lateral sclerosis: a systematic review and meta-analysis
Neurological Sciences · 2025-05 · 46 (5) · 1977-1985
DOI: 10.1007/s10072-025-07994-2 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Neurological Sciences, online erschienen am 17.01.2025. Verfasst von Abdullah Ashraf Hamad und 4 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Menoufia University, Menoufia, 32511, Egypt. abdullah.hamad744@gmail.com. Hauptthemen laut MEDLINE: Amyotrophic Lateral Sclerosis, Superoxide Dismutase-1, Oligonucleotides, Oligonucleotides, Antisense. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Minufiya University.
Abstract (Originalsprache)
Objective
Tofersen, an antisense oligonucleotide, has recently received FDA and EMA approval for treating amyotrophic lateral sclerosis (ALS) in adults with SOD1 gene mutations. This systematic review and meta-analysis synthesized evidence on tofersen’s safety and efficacy in patients with SOD1 -related ALS.
Methods
A comprehensive search of three databases was conducted from inception through October 2024. Eligible studies included clinical trials, observational studies, and case studies. Meta-analyses were conducted using a random-effects model in RevMan.
Results
Twelve studies involving 195 patients treated with tofersen met the inclusion criteria, comprising two randomized controlled trials (RCTs), five cohort studies, one case series, and four case reports. Tofersen demonstrated promising effects, notably reducing SOD1 levels in cerebrospinal fluid and neurofilament light chain (NfL) in plasma, a biomarker strongly correlated with ALS progression and survival. Meta-analysis of RCTs showed a significantly lower rate of decline in ALS Functional Rating Scale-Revised (ALSFRS-R) scores from baseline in the tofersen group compared to placebo (SMD = 0.44, 95% CI [0.05 to 0.83], P = 0.03) and a significant reduction in the decline of predicted Slow Vital Capacity ( P = 0.005). In a pre-post meta-analysis of five studies, a significant decrease in ALS progression rate (ALSFRS-R decline rate) was observed (MD = -0.28, 95% CI [-0.40 to -0.15], P < 0.0001). Reported adverse events were consistent with ALS progression or procedural effects.
Conclusion
Current evidence suggests that tofersen effectively reduces SOD1 and NfL levels and slow disease progression in SOD1 ALS, showing promise as a targeted therapeutic option.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine, Menoufia University, Menoufia, 32511, Egypt. abdullah.hamad744@gmail.com.
- Faculty of Medicine, Mutah University, Al-Karak, Jordan.
- Medical Research Group of Egypt, Negida Academy, Arlington, MA, USA.
- Nursing & Midwifery Research Department (NMRD), Hamad Medical Corporation, Doha, Qatar.
- Department of Public Health, College of Health Sciences, QU Health, Qatar University, Doha, Qatar.
- Department of Neurology, Faculty of Medicine, Al-Azhar University, Cairo, Egypt.
Förderung
- Minufiya University
Zitieren
APA
Hamad, A. A., Alkhawaldeh, I. M., Nashwan, A. J., Meshref, M., & Imam, Y. (2025). Tofersen for SOD1 amyotrophic lateral sclerosis: a systematic review and meta-analysis. Neurological Sciences, 46(5), 1977-1985. https://doi.org/10.1007/s10072-025-07994-2
Vancouver
Hamad AA, Alkhawaldeh IM, Nashwan AJ, Meshref M, Imam Y. Tofersen for SOD1 amyotrophic lateral sclerosis: a systematic review and meta-analysis. Neurological Sciences. 2025;46(5):1977-1985. doi:10.1007/s10072-025-07994-2
BibTeX
@article{Hamad2025,
author = {Hamad, Abdullah Ashraf and Alkhawaldeh, Ibraheem M and Nashwan, Abdulqadir J and Meshref, Mostafa and Imam, Yahia},
title = {Tofersen for SOD1 amyotrophic lateral sclerosis: a systematic review and meta-analysis},
journal = {Neurological Sciences},
year = {2025},
volume = {46},
number = {5},
pages = {1977--1985},
doi = {10.1007/s10072-025-07994-2}
}
EUVIMED